Search results for "Antithrombins"

showing 10 items of 21 documents

Large-scale identification of functional microRNA targeting reveals cooperative regulation of the hemostatic system.

2018

Essentials MicroRNAs (miRNAs) regulate the molecular networks controlling biological functions such as hemostasis. We utilized novel methods to analyze miRNA-mediated regulation of the hemostatic system. 52 specific miRNA interactions with 11 key hemostatic associated genes were identified. Functionality and drugability of miRNA-19b-3p against antithrombin were demonstrated in vivo. SUMMARY: Background microRNAs (miRNAs) confer robustness to complex molecular networks regulating biological functions. However, despite the involvement of miRNAs in almost all biological processes, and the importance of the hemostatic system for a multitude of actions in and beyond blood coagulation, the role o…

0301 basic medicineComputational biologyBiologyAntithrombinsHemostatics03 medical and health sciencesMiceCell Line TumormicroRNAGene silencingAnimalsHumansGene SilencingBiomarker discoveryGene3' Untranslated RegionsHemostasisThree prime untranslated regionRNARobustness (evolution)Computational BiologyHigh-Throughput Nucleotide SequencingThrombosisHematologyMice Inbred C57BLMicroRNAs030104 developmental biologyHemostasisBiomarkersPlasmidsJournal of thrombosis and haemostasis : JTH
researchProduct

Dexamethasone Preconditioning in Cardiac Procedures Reduces Decreased Antithrombin Activity and Is Associated to Beneficial Outcomes: Role of Endothe…

2018

13 páginas, 6 figuras, 2 tablas.

0301 basic medicinemedicine.medical_specialtyEndotheliumAngiogenesisAntithrombinEndotelio.Urology030204 cardiovascular system & hematologyDexamethasonelaw.invention03 medical and health sciences0302 clinical medicineAortic valve replacementlawmedicine.arteryCardiopulmonary bypassMedicinePharmacology (medical)Dexametasona - Uso terapéutico.DexamethasoneOriginal ResearchPharmacologyAortabusiness.industryCardiopulmonary bypasslcsh:RM1-950AntithrombinEndothelium.Antitrombinas.Endothelial functionCardiac surgerymedicine.diseaseAntithrombins.Cardiac surgerylcsh:Therapeutics. Pharmacology030104 developmental biologymedicine.anatomical_structureHeart - Surgery.Dexamethasone - Therapeutic use.Corazón - Cirugía.Angiogenesisbusinessmedicine.drug
researchProduct

Plasma Antithrombin Values Are Significantly Decreased in Coronavirus Disease 2019 (COVID-19) Patients with Severe Illness

2020

2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Plasma AntithrombinSeverity of Illness IndexAntithrombinsCoronavirus Disease 2019medicineHumansThrombophiliaProspective StudiesPlasma Antithrombin Coronavirus Disease 2019 COVID-19business.industryHeparinSARS-CoV-2AntithrombinAnticoagulantsCOVID-19ThrombosisHematologyDisseminated Intravascular CoagulationVirologyCross-Sectional StudiesbusinessCardiology and Cardiovascular Medicinemedicine.drug
researchProduct

Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study

2017

Background and aims: Patients on parenteral nutrition for short bowel syndrome (SBS) have a high risk of thrombotic complications and are often treated with parenteral anticoagulation. Direct oral anticoagulants are absorbed proximally in the digestive tract and may represent alternative regimens in selected SBS patients. In our pilot study, we provided pharmacokinetics parameters of dabigatran etexilate and rivaroxaban in this setting and compared peak (Cmax), trough (Ctrough) concentrations, and areas-under-the-concentration-time-curve (AUC(0) (-) (t)) to reference values retrieved from phase I-III studies. Methods: We enrolled 6 adults with a remaining small bowel length <= 200 cm, norma…

AdultMaleShort Bowel SyndromeParenteral Nutritionmedicine.medical_specialtyCmax030204 cardiovascular system & hematologyGastroenterologyAntithrombinsDabigatran03 medical and health sciences0302 clinical medicineRivaroxabanPharmacokineticsInternal medicinemedicineHumans030212 general & internal medicineDosingAgedRivaroxabanbusiness.industryHematologyMiddle AgedShort bowel syndromemedicine.diseaseCrossover studyDabigatranParenteral nutritionAnesthesiaFemalebusinessmedicine.drugThrombosis Research
researchProduct

Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis

2014

Background— Dabigatran and warfarin have been compared for the treatment of acute venous thromboembolism (VTE) in a previous trial. We undertook this study to extend those findings. Methods and Results— In a randomized, double-blind, double-dummy trial of 2589 patients with acute VTE treated with low-molecular-weight or unfractionated heparin for 5 to 11 days, we compared dabigatran 150 mg twice daily with warfarin. The primary outcome, recurrent symptomatic, objectively confirmed VTE and related deaths during 6 months of treatment occurred in 30 of the 1279 dabigatran patients (2.3%) compared with 28 of the 1289 warfarin patients (2.2%; hazard ratio, 1.08; 95% confidence interval [CI], 0.…

AdultMalemedicine.medical_specialtyRE-COVER IIrecurrenceAntagonists & inhibitorsAdolescentvenous thromboembolismAntithrombinsDabigatranYoung AdultDouble-Blind MethodRisk FactorsPhysiology (medical)Internal medicinemedicineHumansdabigatrancardiovascular diseasesantagonists & inhibitorAgedacute venous thromboembolismHeparinbusiness.industryWarfarinFollow up studiesAnticoagulantsantagonists & inhibitors; hemorrhage; recurrence; thrombin; venous thromboembolism; warfarinHeparinHeparin Low-Molecular-WeightMiddle AgedthrombinSettore MED/11 - Malattie Dell'Apparato CardiovascolarewarfarinHeparin.low molecular weightPooled analysisAnesthesiaAcute Diseasebeta-AlanineBenzimidazolesFemaledabigatran; warfarin; acute venous thromboembolism; RE-COVER IIhemorrhageCardiology and Cardiovascular MedicinebusinessVenous thromboembolismFollow-Up Studiesmedicine.drug
researchProduct

Risk Factors for Intracerebral Hemorrhage in Patients With Atrial Fibrillation on Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention

2021

Background and Purpose: Clinical trials on stroke prevention in patients with atrial fibrillation have consistently shown clinical benefit from either warfarin or non–vitamin K antagonist oral anticoagulants (NOACs). NOAC-treated patients have consistently reported to be at lower risk for intracerebral hemorrhage (ICH) than warfarin-treated patients. The aims of this prospective, multicenter, multinational, unmatched, case-control study were (1) to investigate for risk factors that could predict ICH occurring in patients with atrial fibrillation during NOAC treatment and (2) to evaluate the role of CHA 2 DS 2 -VASc and HAS-BLED scores in the same setting. Methods: Cases were consecutive pa…

MaleAdministration Oral030204 cardiovascular system & hematologySettore MED/110302 clinical medicine80 and overrisk factorsMedicineatrial fibrillationProspective StudiesAged 80 and overatrial fibrillation; cerebral hemorrhage; logistic models; risk factors; white matter; Administration Oral; Aged; Aged 80 and over; Antithrombins; Atrial Fibrillation; Case-Control Studies; Cerebral Hemorrhage; Female; Humans; Male; Middle Aged; Prospective Studies; Risk Factors; StrokeAtrial fibrillationMiddle AgedVitamin K antagonist3. Good healthStrokeAdministrationSettore MED/26 - NeurologiaFemaleCardiology and Cardiovascular Medicinewhite mattermedicine.drugOralmedicine.medical_specialtymedicine.drug_classSettore MED/26Lower riskAntithrombins03 medical and health sciencesInternal medicineHumanscardiovascular diseaseslogistic modelAgedAdvanced and Specialized NursingIntracerebral hemorrhagecerebral hemorrhagebusiness.industryWarfarinmedicine.diseaseClinical trialatrial fibrillation; cerebral hemorrhage; logistic models; risk factors; white matterCase-Control StudiesConcomitantHeart failureNeurology (clinical)businesslogistic models030217 neurology & neurosurgeryStroke
researchProduct

Recanalization Therapies in Acute Ischemic Stroke Patients Impact of Prior Treatment With Novel Oral Anticoagulants on Bleeding Complications and Out…

2015

Background— We explored the safety of intravenous thrombolysis (IVT) or intra-arterial treatment (IAT) in patients with ischemic stroke on non-vitamin K antagonist oral anticoagulants (NOACs, last intake &lt;48 hours) in comparison with patients (1) taking vitamin K antagonists (VKAs) or (2) without previous anticoagulation (no-OAC). Methods and Results— This is a multicenter cohort pilot study. Primary outcome measures were (1) occurrence of intracranial hemorrhage (ICH) in 3 categories: any ICH (ICH any ), symptomatic ICH according to the criteria of the European Cooperative Acute Stroke Study II (ECASS-II) (sICH ECASS-II ) and the National Institute of Neurological Disorders and Stroke …

MaleBrain Ischemia/blood/drug therapyVitamin Kmedicine.medical_treatmentendovascular proceduresAnticoagulants/administration & dosage/adverse effects/classification/therapeutic useAdministration OralPilot ProjectsTissue plasminogen activatorBrain IschemiaCohort Studies2737 Physiology (medical)Atrial Fibrillation80 and overThrombolytic TherapyVitamin K/antagonists & inhibitorsStrokethrombolytic therapyAged 80 and overIncidenceAtrial fibrillationThrombolysisMiddle Aged3. Good healthvitamin K antagonistsTreatment OutcomeAdministrationAcute DiseaseCohortCerebral Hemorrhage/chemically induced/epidemiologyFemaleCardiology and Cardiovascular MedicineAtrial Fibrillation/complicationsmedicine.drugOralmedicine.medical_specialtyanticoagulantsnon-vitamin K antagonist oral anticoagulantsFactor Xa Inhibitors/administration & dosage/adverse effects/therapeutic useintracranial hemorrhagesintra-arterial treatment610 Medicine & healthAntithrombins2705 Cardiology and Cardiovascular MedicineDabigatranFibrinolytic AgentsPhysiology (medical)Internal medicinemedicineischemic strokeHumansAgedCerebral HemorrhageIntracerebral hemorrhageFibrinolytic Agents/therapeutic usebusiness.industryAntithrombins/administration & dosage/adverse effects/therapeutic usemedicine.diseaseddc:616.810040 Clinic for Neurologyanticoagulants; endovascular procedures; intra-arterial treatment; intracranial hemorrhages; ischemic stroke; non-vitamin K antagonist oral anticoagulants; thrombolytic therapy; vitamin K antagonistsPropensity score matchingbusinessFactor Xa InhibitorsCirculation
researchProduct

Argatroban for elective percutaneous coronary intervention: The ARG-E04 multi-center study

2011

The synthetic arginine-derived direct thrombin inhibitor argatroban is an attractive anticoagulant for percutaneous coronary intervention (PCI), because of its rapid onset and offset, and its hepatic elimination. Argatroban was approved for PCI in patients with heparin-induced thrombocytopenia (HIT). However, there are limited data about argatroban in non-HIT patients. The objective of this open-label, multiple-dose, controlled study was to examine the safety and efficacy of argatroban in patients undergoing elective PCI.Of 140 patients randomized to three argatroban dose groups (ARG250, ARG300, and ARG350 with 250, 300, or 350 μg/kg bolus, followed by 15, 20, or 25 μg/kg/min infusion) and …

Malemedicine.drug_classmedicine.medical_treatmentActivated clotting timeHemorrhageArginineAntithrombinsArgatrobanBolus (medicine)medicineHumansAngina UnstableMyocardial infarctionAngioplasty Balloon CoronaryBlood CoagulationAgedSulfonamidesDose-Response Relationship Drugmedicine.diagnostic_testHeparinbusiness.industryAnticoagulantAnticoagulantsPercutaneous coronary interventionThrombosisMiddle Agedmedicine.diseaseDirect thrombin inhibitorPipecolic AcidsAnesthesiaConventional PCIFemaleCardiology and Cardiovascular MedicinebusinessFollow-Up Studiesmedicine.drugInternational Journal of Cardiology
researchProduct

Postoperative Costs Associated With Outcomes After Cardiac Surgery With Extracorporeal Circulation: Role of Antithrombin Levels

2012

Objective: To study the impact on postoperative costs of a patient's antithrombin levels associated with outcomes after cardiac surgery with extracorporeal circulation. Design: An analytic decision model was designed to estimate costs and clinical outcomes after cardiac surgery in a typical patient with low antithrombin levels (= 63.7%). The data used in the model were obtained from a literature review and subsequently validated by a panel of experts in cardiothoracic anesthesiology. Setting: Multi-institutional (14 Spanish hospitals). Participants: Consultant anesthesiologists. Measurements and Main Results: A sensitivity analysis of extreme scenarios was carried out to assess the impact o…

Malemedicine.medical_specialtyExtracorporeal Circulationextracorporeal circulationCardiotonic AgentsMyocardial InfarctionAntithrombinsDrug Costslaw.inventionPostoperative ComplicationsDrug TherapylawSurveys and QuestionnairesThromboembolismAtrial FibrillationmedicineCardiopulmonary bypassHumansBlood TransfusionCardiac Surgical ProceduresCardiothoracic anesthesiologyAverage costAgedPostoperative Carebusiness.industryAntithrombinExtracorporeal circulationDecision TreesAntithrombin ActivityLength of StayMiddle AgedSurgeryCardiac surgeryStrokeIntensive Care UnitsantithrombinAnesthesiology and Pain MedicineTreatment OutcomeSpainHealth Care SurveysEmergency medicineCosts and Cost AnalysisFemaleKidney DiseasesCardiology and Cardiovascular Medicinebusinesscardiopulmonary bypassHospital staymedicine.drug
researchProduct

Glucocorticoids as modulators of expression and activity of Antithrombin (At): potential clinical relevance.

2014

Abstract Introduction An inverse relationship has been reported between decreased postoperative Antithrombin (AT) plasmatic levels and the incidence of complications. We hypothesized that Nuclear Hormone Receptors could modulate the expression of SERPINC1 , encoding AT, through a Hormone Regulatory Element present in its promoter, and thus hormone analogs could be a pharmacological complement in surgical procedures to activate endogenous AT synthesis. Materials and Methods The expression of SERPINC1 was analyzed in HepG2 cells by quantitative RT-PCR and Western Blot. Two studies were conducted with (a) patients submitted to cardiac surgery with cardiopulmonary bypass receiving (n =17) or no…

Malemedicine.medical_specialtyMolecular Sequence DataReceptors Cytoplasmic and NuclearRetinoid X receptorLigandsAntithrombinsCohort StudiesRetinoidsInternal medicinemedicineHumansGlucocorticoidsDexamethasoneAgedCardiopulmonary BypassBase Sequencebusiness.industryAntithrombinRNA-Binding ProteinsHematologyHep G2 CellsIsoxazolesMiddle AgedEndocrinologyRetinoid X ReceptorsTreatment OutcomeMethylprednisoloneNuclear receptorHemostasisFemaleCortisonebusinessHormonemedicine.drugThrombosis research
researchProduct